SVB Securities analyst Mani Foroohar raised the firm’s price target on Moderna (MRNA) to $111 from $102 and keeps a Market Perform rating on the shares after the company announced positive topline data from the ConquerRSV Phase 3 pivotal trial of its respiratory syncytial virus vaccine, mRNA-1345, in older adults. Based on high level comparison with VE from RSV vaccines from competitors Pfizer (PFE), GSK (GSK), and Johnson & Johnson (JNJ), the analyst sees these results as likely approvable and plausibly competitive with those agents – though this limited, topline disclosure offers an incomplete picture for comparison, and any numerical differences should consequently be taken with a grain of salt.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRNA:
- Moderna (NASDAQ:MRNA) Touts 84% Vaccine Efficacy; Stock Rises
- Moderna announces data from efficacy trial of mRNA-1345 targeting RSV
- FDA sees preliminary safety signal for older users of Pfizer bivalent vaccine
- Moderna price target raised to $225 from $185 at Deutsche Bank
- Senator Sanders says Moderna COVID vaccine pricing shows ‘unacceptable’ greed